]>
IRCT20190303042893N1 IRCT 2019-03-17 Arak University of Medical Sciences The effect of Monteluca on the symptoms of pyelonephritis in children Evaluation of Effect of Montelukast on the Symptoms of Pyelonephritis in Children. 2019-03-11 anticipated 100 Complete https://irct.ir/trial/37948 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In order to randomization we will use the block method, Accordingly, the patients under study are divided into two groups. The allocation of patients in two groups was based on demographic characteristics and their matching. Based on this, after considering the patients' demographic data, patients were divided into two equal groups of patients, they enrolled in the study and performed desired intervention on them, Blinding description: This means that patients in groups do not know the used drugs. 4 Pyelonephritis. Intervention 1: Intervention group: In the first group, Montelukast is prescribed at a dose of 5 mg/day. Intervention 2: Control group: In the first group, only the usual treatments of pyelonephritis is used. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information
public Hasan Taher Ahmadi
Clinical Research Development Center of Amirkabir Hospital
Arak Iran (Islamic Republic of) 3848176941 +98 86 3313 5075 HasanTaherAhmadi@gmail.com Arak University of Medical Sciences scientific Parsa Yousefi Chayjan
Clinical Research Development Center of Amirkabir Hospital
Arak Iran (Islamic Republic of) 3848176941 +98 86 3417 3526 ParsaYousefi23@gmail.com Arak University of Medical Sciences Iran (Islamic Republic of) Patients with pyelonephritis with clinical symptoms of pyelonephritis and satisfaction with the studyThey are selected as the study group. Satisfaction to participate in the study 3 years 18 years Both Children with underlying illness of kidney, liver and heart. N10 Acute tubulo-interstitial nephritis Treatment - Drugs Treatment - Drugs Intervention group: In the first group, Montelukast is prescribed at a dose of 5 mg/day. Control group: In the first group, only the usual treatments of pyelonephritis is used. Symptoms of Pyelonephritis. Timepoint: Before taking the drug and 14 days after taking medication. Method of measurement: Registration of symptoms in the checklist. Arak University of Medical Sciences Approved 2019-03-04 Ethics Committee of Arak University of Medical Sciences and Health Services Deputy of research and t Student Research Committee, Arak University of Medical Sciences, Arak, Iran Arak Markazi Iran (Islamic Republic of)